#1 Clinical Trials Search in Europe

Lapatinib

This article explores the use of Lapatinib, a targeted cancer drug, in various clinical trials. Lapatinib is being studied for its effectiveness in treating different types of cancer, particularly breast cancer. The trials aim to evaluate the drug’s efficacy, safety, and its ability to penetrate tumors and the brain. Understanding these trials can provide valuable insights into potential new treatment options for cancer patients.

Table of Contents

What is LAPATINIB?

LAPATINIB is a medication used in the treatment of certain types of breast cancer. It’s also known by other names such as Tykerb, Tyverb, and GW572016[1]. LAPATINIB is a type of drug called a tyrosine kinase inhibitor, which means it works by blocking specific proteins that are involved in cancer growth[2].

How LAPATINIB Works

LAPATINIB targets two specific proteins called HER1 (also known as EGFR) and HER2. These proteins are often found in higher amounts on the surface of some cancer cells, especially in certain types of breast cancer. By blocking these proteins, LAPATINIB can help to slow down or stop the growth of cancer cells[1].

The drug works inside the cancer cells to interrupt the signaling pathways that promote cell growth and survival. This can lead to the death of cancer cells and shrinkage of tumors[1].

Conditions Treated with LAPATINIB

LAPATINIB is primarily used to treat certain types of breast cancer. Specifically, it’s used for:

  • HER2-positive metastatic breast cancer: This is breast cancer that has spread to other parts of the body and has high levels of the HER2 protein[3].
  • Advanced or metastatic breast cancer: In patients who have already been treated with other therapies[4].
  • Hormone receptor-positive metastatic breast cancer: In postmenopausal women, when used in combination with an aromatase inhibitor[3].

In some clinical trials, LAPATINIB has also been studied for use in other types of cancer, such as bladder cancer[5].

Dosage and Administration

LAPATINIB is taken orally in tablet form. The dosage can vary depending on the specific condition being treated and whether it’s being used alone or in combination with other drugs. Some common dosages include:

  • 1250 mg (5 tablets) taken once daily when used with capecitabine[3].
  • 1500 mg taken once daily when used alone[2].

It’s important to take LAPATINIB exactly as prescribed by your doctor. The medication should be taken at least one hour before or one hour after a meal[2].

Clinical Studies and Efficacy

Several clinical studies have been conducted to evaluate the effectiveness of LAPATINIB:

  • In a study of patients with HER2-positive metastatic breast cancer, LAPATINIB combined with capecitabine showed improved progression-free survival compared to capecitabine alone[3].
  • Another study looked at LAPATINIB as a neoadjuvant therapy (treatment given before the main treatment) in patients with locally advanced HER2-positive breast cancer. After 6 weeks of treatment, some patients showed tumor shrinkage[1].

Side Effects and Safety

Like all medications, LAPATINIB can cause side effects. Common side effects may include:

  • Diarrhea
  • Nausea
  • Rash
  • Fatigue
  • Loss of appetite

More serious side effects can occur, including liver problems and heart problems. Your doctor will monitor you closely for these potential side effects[6].

Combination Therapies

LAPATINIB is often used in combination with other cancer treatments. Some common combinations include:

  • LAPATINIB with capecitabine (Xeloda): This combination is used in patients with advanced or metastatic HER2-positive breast cancer[3].
  • LAPATINIB with letrozole: This combination is used in postmenopausal women with hormone receptor-positive and HER2-positive metastatic breast cancer[3].
  • LAPATINIB with trastuzumab (Herceptin): This combination has been studied in clinical trials for patients with HER2-positive breast cancer[7].

These combinations may offer improved efficacy compared to single-drug treatments in certain patient populations.

Aspect Details
Drug Name Lapatinib (also known as GW572016, Tykerb, Tyverb)
Main Cancer Types Studied Breast cancer, endometrial cancer, head and neck cancer, vestibular schwannomas
Mechanism of Action Dual inhibitor of HER1 and HER2 tyrosine kinases
Administration Oral, typically once daily
Dosage Range 500 mg to 1500 mg daily, varying by trial
Key Objectives Assess efficacy, safety, tumor penetration, brain penetration, survival impact
Combination Therapies Tested with capecitabine in some trials
Special Investigations Brain and tumor penetration studies using PET scans

FAQ

  • What is Lapatinib? Lapatinib is an oral drug that inhibits HER1 and HER2, proteins involved in cancer cell growth. It's being studied for treating various cancers, especially HER2-positive breast cancer.
  • What types of cancer is Lapatinib being tested for? Lapatinib is primarily being tested for breast cancer, but trials also include endometrial cancer, head and neck cancer, and vestibular schwannomas (a type of non-cancerous tumor).
  • How is Lapatinib administered in these trials? In most trials, Lapatinib is given orally, usually once daily. The dosage varies between trials, ranging from 500 mg to 1500 mg per day.
  • What are the main goals of these Lapatinib clinical trials? The main goals include assessing Lapatinib's effectiveness in shrinking tumors, its safety profile, its ability to penetrate the brain and tumors, and its impact on patients' survival and quality of life.
  • Are there any combination therapies being tested with Lapatinib? Yes, some trials are testing Lapatinib in combination with other drugs. For example, one study is evaluating Lapatinib with capecitabine for head and neck cancer treatment.

Ongoing Clinical Trials on Lapatinib

  • Long-Term Study on Early Stage Breast Cancer Patients Using Capecitabine, Gemcitabine, and Paclitaxel

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Binimetinib, Lapatinib, and Vinorelbine for Patients with RAS-Mutated Metastatic Colorectal Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study on Advanced Soft-Tissue Sarcoma: Testing Futibatinib and Drug Combination for Patients with Unresectable or Metastatic Conditions

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • HER2: A protein that promotes the growth of cancer cells. Some breast cancers have higher levels of HER2, making them HER2-positive.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it worsening.
  • RECIST: Response Evaluation Criteria In Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Vestibular schwannoma: A non-cancerous tumor that develops on the nerve connecting the ear to the brain.
  • Biomarker: A measurable substance in the body that can indicate the presence of disease, infection, or environmental exposure.
  • PET scan: Positron Emission Tomography, an imaging test that uses a radioactive drug to show how organs and tissues are functioning.

References

  1. https://clinicaltrials.gov/study/NCT00206427
  2. https://clinicaltrials.gov/study/NCT00820924
  3. https://clinicaltrials.gov/study/NCT01808573
  4. https://clinicaltrials.gov/study/NCT00462956
  5. https://clinicaltrials.gov/study/NCT01245660
  6. https://clinicaltrials.gov/study/NCT00975988
  7. https://clinicaltrials.gov/study/NCT00482391